December 23, 2019 — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for its in-house discovered and developed orexin…Original Article
FDA Approves Dayvigo (lemborexant) for the Treatment of Insomnia in Adult Patients
